Healthcare entity
Of the tracked stories, 1 of 2 also mention Center for Drug Evaluation, the most common co-covered peer. The 92-day window averages about 0.2 stories each week. Source depth averages 6 original sources per story, versus 3.7 across the same-window beat baseline.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Center for Drug Evaluation, the most common co-covered peer. The 92-day window averages about 0.2 stories each week. Source depth averages 6 original sources per story, versus 3.7 across the same-window beat baseline. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 7, the average consequence score sits above the same-window beat average of 6.4. National Medical Products Administration appears in 2 tracked Healthcare stories published from March 25, 2026 through June 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 78 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering National Medical Products Administration. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
National Medical Products Administration is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
